Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
Author
Richard, ShambaviChari, Ajai
Delimpasi, Sosana
Simonova, Maryana
Spicka, Ivan
Pour, Ludek
Kriachok, Iryna
Dimopoulos, Meletios A
Pylypenko, Halyna
Auner, Holger W
Leleu, Xavier
Usenko, Ganna
Hajek, Roman
Benjamin, Reuben
Dolai, Tuphan Kanti
Sinha, Dinesh Kumar
Venner, Christopher P
Garg, Mamta
Stevens, Don Ambrose
Quach, Hang
Jagannath, Sundar
Moreau, Phillipe
Levy, Moshe
Badros, Ashraf
Anderson, Larry D
Bahlis, Nizar J
Facon, Thierry
Mateos, Maria Victoria
Cavo, Michele
Chang, Hua
Landesman, Yosef
Chai, Yi
Arazy, Melina
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G
Grosicki, Sebastian
Richardson, Paul G
Date
2021-06-01Journal
American Journal of HematologyPublisher
Wiley-BlackwellType
Article
Metadata
Show full item recordAbstract
In the phase 3 BOSTON study, patients with multiple myeloma (MM) after 1–3 prior regimens were randomized to once-weekly selinexor (an oral inhibitor of exportin 1 [XPO1]) plus bortezomib-dexamethasone (XVd) or twice-weekly bortezomib-dexamethasone (Vd). Compared with Vd, XVd was associated with significant improvements in median progression-free survival (PFS), overall response rate (ORR), and lower rates of peripheral neuropathy, with trends in overall survival (OS) favoring XVd. In BOSTON, 141 (35.1%) patients had MM with high-risk (presence of del[17p], t[4;14], t[14;16], or ≥4 copies of amp1q21) cytogenetics (XVd, n = 70; Vd, n = 71), and 261 (64.9%) exhibited standard-risk cytogenetics (XVd, n = 125; Vd, n = 136). Among patients with high-risk MM, median PFS was 12.91 months for XVd and 8.61 months for Vd (HR, 0.73 [95% CI, (0.4673, 1.1406)], p = 0.082), and ORRs were 78.6% and 57.7%, respectively (OR 2.68; p = 0.004). In the standard-risk subgroup, median PFS was 16.62 months for XVd and 9.46 months for Vd (HR 0.61; p = 0.004), and ORRs were 75.2% and 64.7%, respectively (OR 1.65; p = 0.033). The safety profiles of XVd and Vd in both subgroups were consistent with the overall population. These data suggest that selinexor can confer benefits to patients with MM regardless of cytogenetic risk. ClinicalTrials.gov identifier: NCT03110562. © 2021 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.Rights/Terms
© 2021 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.Identifier to cite or link to this item
http://hdl.handle.net/10713/16162ae974a485f413a2113503eed53cd6c53
10.1002/ajh.26261
Scopus Count
Collections
Related articles
- Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
- Authors: Mateos MV, Gavriatopoulou M, Facon T, Auner HW, Leleu X, Hájek R, Dimopoulos MA, Delimpasi S, Simonova M, Špička I, Pour L, Kriachok I, Pylypenko H, Doronin V, Usenko G, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Stevens DA, Quach H, Jagannath S, Moreau P, Levy M, Badros AZ, Anderson LD Jr, Bahlis NJ, Cavo M, Chai Y, Jeha J, Arazy M, Shah J, Shacham S, Kauffman MG, Richardson PG, Grosicki S
- Issue date: 2021 Apr 13
- Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
- Authors: Auner HW, Gavriatopoulou M, Delimpasi S, Simonova M, Spicka I, Pour L, Dimopoulos MA, Kriachok I, Pylypenko H, Leleu X, Doronin V, Usenko G, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Stevens DA, Quach H, Jagannath S, Moreau P, Levy M, Badros A, Anderson LD Jr, Bahlis NJ, Facon T, Mateos MV, Cavo M, Chai Y, Arazy M, Shah J, Shacham S, Kauffman MG, Richardson PG, Grosicki S
- Issue date: 2021 Jun 1
- Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
- Authors: Dolph M, Tremblay G, Leong H
- Issue date: 2021 Nov
- Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
- Authors: Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD Jr, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S
- Issue date: 2020 Nov 14
- Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma.
- Authors: Dolph M, Tremblay G, Gilligan AM, Leong H
- Issue date: 2021